Stanozolol supplier | CasNO.10418-03-8

Name
Stanozolol
EINECS 233-894-8
CAS No. 10418-03-8
Density 1.129 g/cm³
Solubility
Melting Point 242 °C
Formula C₂₁H₃₂N₂O
Boiling Point 490.8 °C at 760 mmHg
Molecular Weight 328.498
Flash Point 250.7 °C
Transport Information
Appearance white to light yellow powder
Safety 53-22-36/37/39-36-26
Risk Codes 63
Molecular Structure
Hazard Symbols Xn,Xi
Synonyms 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI);17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol;17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol;17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole;17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole;Anabol;Androstanazol;Androstanazolestanazol;Estazol;Stanazolol;Stromba;Strombaject;Tevabolin;Win 14833;Winstrol;
PSA 48.91000
LogP 4.11810

Synthetic route

17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one: 17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one

: 10418-03-8
stanozolol

Conditions

Conditions	Yield
With hydrazine

: 10418-03-8
stanozolol

: 7693-46-1
4-Nitrophenyl chloroformate

: tanozolol-4-nitrophenyl-carbonate

Conditions

Conditions	Yield
With triethylamine In dichloromethane at 20℃; for 3h; pH=8.5;	76.85%

: 10418-03-8
stanozolol

: 17,17-dimethyl-18-nor-5α-androst-13(14)-eno<3,2-c>pyrazole

Conditions

Conditions	Yield
With hydrogenchloride for 0.25h; Ambient temperature;	66%

: 10418-03-8
stanozolol

: 124-63-0
methanesulfonyl chloride

: 107000-35-1
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-8-Methanesulfonyl-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-ol

Conditions

Conditions	Yield
With pyridine at 0 - 20℃; for 1h;	56%

: 14660-52-7
ethyl 5-bromovalerate

: 10418-03-8
stanozolol

A: ethyl-5-{17β-hydroxy-17α-methylpyrazolo[3′,4′:3,2]-5α-androstan-1′-yl}pentanoate

B: ethyl 5-{17α-methyl-17β-hydroxypyrazolo[4′,5′:2,3]-5α-androstan-1′-yl}pentanoate

Conditions

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 80℃; for 5h; Microwave irradiation;	A 38% B 28%

...Expand

: 10418-03-8
stanozolol

: 21085-72-3
1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester

A: 2′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

B: 1′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

Conditions

Conditions	Yield
With mercury(II) cyanide; mercury dibromide In nitromethane; benzene for 3h;	A 17% B 5%

...Expand

: 110-86-1
pyridine

: 10418-03-8
stanozolol

: stanozolol 17β-sulfate pyridinium salt

Conditions

Conditions	Yield
With chlorosulfonic acid 1.) -5 deg C, 2.) RT, 3 h; Yield given. Multistep reaction;

: 10418-03-8
stanozolol

: Sulfuric acid mono-((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl) ester

Conditions

Conditions	Yield
With sulfur trioxide pyridine complex In N,N-dimethyl-formamide for 2h; Ambient temperature;

: 10418-03-8
stanozolol

: 145841-85-6, 125636-91-1
17-epistanozolol

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: sulfur trioxide pyridine complex / dimethylformamide / 2 h / Ambient temperature 2: K2CO3 / dimethylformamide; H2O / 72 h View Scheme

: 2174-58-5
L-malic acid

: 10418-03-8
stanozolol

: ((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*(S-methylsuccinic acid)

Conditions

Conditions	Yield
In methanol Milling;

: 3641-51-8
2-(R)-methylsuccinic acid

: 10418-03-8
stanozolol

: ((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*2(R-methylsuccinic acid)

Conditions

Conditions	Yield
In methanol Milling;

: 10418-03-8
stanozolol

: C21H30N2O

Conditions

Conditions	Yield
With titanium(IV) oxide In water; acetonitrile Reagent/catalyst; UV-irradiation;

: 10418-03-8
stanozolol

: 1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑1′‑yl)‑β‑d‑glucopyranuronic acid

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h 2.1: lithium hydroxide monohydrate / methanol; water / 7 h / 20 °C 2.2: amberlite 120 ion resin / 0.25 h View Scheme

: 10418-03-8
stanozolol

: 1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑2′‑yl)‑β‑d‑glucopyranuronic acid

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h 2.1: lithium hydroxide monohydrate / methanol; water / 6 h / 20 °C 2.2: amberlite 120 ion resin / 0.25 h View Scheme

: 10418-03-8
stanozolol

: C44H72N6O7S

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation 2: sodium hydroxide; methanol / water / 1.5 h / 20 °C 3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere View Scheme

: 10418-03-8
stanozolol

: C43H68N6O8S

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C 2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C 3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation 4: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere View Scheme

Yield

Multi-step reaction with 4 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation
4: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme

: 10418-03-8
stanozolol

: C30H43N3O5

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation 2: sodium hydroxide; methanol / water / 1.5 h / 20 °C 3: dicyclohexyl-carbodiimide / N,N-dimethyl-formamide / 20 °C View Scheme

: 10418-03-8
stanozolol

: C26H40N2O3

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation 2: sodium hydroxide; methanol / water / 1.5 h / 20 °C View Scheme

: 10418-03-8
stanozolol

: C26H40N2O3

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation 2: sodium hydroxide; methanol / water / 1.5 h / 20 °C View Scheme

: 10418-03-8
stanozolol

: 17α-methyl pyrazolo[3′,4′:3,2]-5α-androstane-17β-yl-hemisuccinate

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C 2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C 3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation View Scheme

: 10418-03-8
stanozolol

: C44H72N6O7S

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation 2: sodium hydroxide; methanol / water / 1.5 h / 20 °C 3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere View Scheme

: 24424-99-5
di-tert-butyl dicarbonate

: 10418-03-8
stanozolol

A: Boc-stanozolol

B: C26H40N2O3

Conditions

Conditions	Yield
With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃;

...Expand

: 24424-99-5
di-tert-butyl dicarbonate

: 10418-03-8
stanozolol

: C35H56N2O6Si

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C 2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C View Scheme

: 10418-03-8
stanozolol

: C26H38N2O4

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: dmap / dichloromethane / 72 h 2: sodium hydroxide / methanol / 1 h / 20 °C View Scheme

: 10418-03-8
stanozolol

: 1490-25-1
succinic acid monomethylester chloride

A: C26H38N2O4

B: C26H38N2O4

Conditions

Conditions	Yield
With dmap In dichloromethane for 2h;

...Expand

: 10418-03-8
stanozolol

: 1490-25-1
succinic acid monomethylester chloride

A: C31H44N2O7

B: C31H44N2O7

Conditions

Conditions	Yield
With dmap In dichloromethane for 72h; Overall yield = 90 percent;

...Expand

Stanozolol Specification

The systematic name of Stanozolol is (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol. With the CAS registry number 10418-03-8, it is also named as 17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol. The product's categories are pharmaceutical; active pharmaceutical ingredients; biochemistry; steroids. It is white to light yellow powder which was developed by Winthrop Laboratories in 1962. And it is a synthetic anabolic steroid derived from testosterone, and has been approved by the FDA for human use. But in the United States, like other anabolic steroids, stanozolol is classified as a controlled substance under federal regulation.

The other characteristics of this product can be summarized as: (1)ACD/LogP: 5.53; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 5.52; (4)ACD/LogD (pH 7.4): 5.53; (5)ACD/BCF (pH 5.5): 9063.27; (6)ACD/BCF (pH 7.4): 9432.91; (7)ACD/KOC (pH 5.5): 23400.01; (8)ACD/KOC (pH 7.4): 24354.36; (9)#H bond acceptors: 3; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 1; (12)Index of Refraction: 1.573; (13)Molar Refractivity: 95.87 cm³; (14)Molar Volume: 290.8 cm³; (15)Polarizability: 38×10^-24 cm³; (16)Surface Tension: 48.8 dyne/cm; (17)Enthalpy of Vaporization: 79.77 kJ/mol; (18)Vapour Pressure: 1.89E-10 mmHg at 25°C; (19)Tautomer Count: 2; (20)Exact Mass: 328.251464; (21)MonoIsotopic Mass: 328.251464; (22)Topological Polar Surface Area: 48.9; (23)Heavy Atom Count: 24.

Preparation: The pyrazole ring in stanozolol can be prepared by the condensation of a keto-aldehyde with hydrazine.

Uses of Stanozolol: It is used in chronic wasting disease, weight loss of illness and after surgery, elderly and frail, osteoporosis, stunted children, aplastic anemia and so on. Stanozolol is commonly used by athletes and bodybuilders alike to lose fat while retaining lean body mass. Additionly, it is preferred by many steroid users due to the fact that it causes strength increases without excess weight-gain, promotes increases in vascularity, and will not convert to estrogen.

When you are using this chemical, please be cautious about it as the following:
It is possible risk of harm to the unborn child, so people should not breathe dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. If you want to contact this product, you must wear suitable protective clothing, gloves and eye/face protection. Additionally, avoid exposure - obtain special instructions before use.

People can use the following data to convert to the molecule structure.
1. SMILES:O[C@@]5(C)CC[C@H]4[C@H]3[C@@H]([C@]2(Cc1c(nnc1)C[C@@H]2CC3)C)CC[C@@]45C
2. InChI:InChI=1/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1

Product Name

Stanozolol

Synthetic route

Stanozolol Specification

Related Products

Hot Products